Cyclacel Pharma (CYCC) Reports Q3 Loss of $0.86
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts CYCC Hot Sheet
Price: $6.37 --0%
Financial Fact:
Selling, general and administrative: 1.27M
Today's EPS Names:
PFBX, GOVB, VABK, More
Financial Fact:
Selling, general and administrative: 1.27M
Today's EPS Names:
PFBX, GOVB, VABK, More
Join SI Premium – FREE
Cyclacel Pharma (NASDAQ: CYCC) reported Q3 EPS of ($0.86), versus ($0.91) reported last year. Revenue for the quarter came in at $0 , versus $0 reported last year.
For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SPS Commerce (SPSC) Tops Q3 EPS by 16c; Offers Guidance
- Mohawk Industries (MHK) Tops Q3 EPS by 14c; offers guidance
- Chain Bridge Bancorp, Inc. (CBNA) Tops Q3 EPS by 166c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
